Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, is pleased to
announce the detailed voting results on the items of business considered
at its Annual General Meeting of Shareholders held on May 2, 2019 (the “Meeting”).
Shareholder Voting Results
The Shareholders voted on the following matters at this year’s Meeting.
Proposal 1 – Election of Directors
The nominees listed in Zymeworks’ proxy statement dated March 18, 2019
(the “Proxy Statement”) were elected as Directors of the Company.
Detailed results of the votes are set out below:
|
Proposal 1
|
Outcome of the Vote
|
|
|
Votes by Ballot
|
|
Election of Directors
|
|
|
Votes For
|
|
|
Votes Withheld
|
|
Kenneth Hillan
|
Carried
|
|
|
18,394,190
(99.92%)
|
|
|
14,339
(0.08%)
|
|
Natalie Sacks
|
Carried
|
|
|
18,395,416
(99.93%)
|
|
|
13,113
(0.07%)
|
Proposal 2 – Appointment of Auditors
The vote was carried for the Appointment of the Auditors, KPMG LLP.
Detailed results of the votes are set out below:
|
Proposal 2
|
Outcome of the Vote
|
|
|
Votes by Ballot
|
|
|
|
|
Votes For
|
|
|
Votes Withheld
|
|
Appointment of KPMG LLP
|
Carried
|
|
|
23,430,739
(99.88%)
|
|
|
28,799
(0.12%)
|
Full details of all proposals are fully described in the Proxy Statement
available on the Company’s profile on SEDAR at www.sedar.com,
and on EDGAR at www.sec.gov,
and the detailed results of voting on each proposal are included in the
Report of Voting Results filed on SEDAR and on EDGAR.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the
development of next-generation multifunctional biotherapeutics. The
Company’s suite of therapeutic platforms and its fully integrated drug
development engine enable precise engineering of highly differentiated
product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel
AzymetricTM bispecific antibody currently in Phase 2 clinical
development. The Company’s second clinical candidate, ZW49, is a
bispecific antibody-drug conjugate currently in Phase 1 clinical
development and combines the unique design and antibody framework of
ZW25 with Zymeworks’ proprietary ZymeLinkTM cytotoxic
payload. Zymeworks is also advancing a deep preclinical pipeline in
immuno-oncology and other therapeutic areas. In addition, its
therapeutic platforms are being leveraged through multiple strategic
partnerships with eight global biopharmaceutical companies. For more
information, visit www.zymeworks.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190503005094/en/
Copyright Business Wire 2019